GlassScriptPhysician profile
Peter G Wilcox
NPI 1285049965
$15,563.36
in general payments reported to CMS, 2019-2025
45 companies · $5,506 in 2025
The $5,506 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,756 · 2022: $3,315 · 2023: $2,800 · 2024: $2,186 · 2025: $5,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,177 · Consulting Fee: $3,550 · Travel and Lodging: $656 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,177.09 |
| Consulting Fee | $3,550.00 |
| Travel and Lodging | $655.50 |
| Education | $109.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,934.53 | 2024-2025 | |
| Amgen INC. | $1,463.67 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,412.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,187.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Alexion Pharmaceuticals, INC. | $1,137.84 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $860.99 | 2021-2025 | Jardiance, Tradjenta, Glyxambi |
| Xeris Pharmaceuticals, INC. | $536.80 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $422.55 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $404.64 | 2021-2025 | |
| Corcept Therapeutics | $401.24 | 2021-2023 | Korlym |
| Abbott Laboratories | $371.37 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $364.68 | 2021-2025 | |
| Insulet Corporation | $277.01 | 2021-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $266.55 | 2021-2025 | Farxiga, Lokelma |
| Amphastar Pharmaceuticals, INC. | $224.89 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $222.40 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $222.21 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $208.97 | 2021-2025 | Tymlos |
| Dexcom, INC. | $182.44 | 2021-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $155.49 | 2021-2024 | Isturisa, Signifor Lar |
| Mannkind Corporation | $144.79 | 2023-2025 | Afrezza |
| Abbvie INC. | $127.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $120.27 | 2021-2024 | Xarelto |
| Ascensia Diabetes Care US INC. | $108.40 | 2023-2024 | |
| Medtronic, INC. | $101.14 | 2022-2023 | Intellis Adaptivestim |
| Beta Bionics, INC. | $78.66 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kyowa Kirin, INC. | $70.11 | 2023-2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $56.55 | 2023 | |
| Antares Pharma, INC. | $53.00 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $48.33 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $46.32 | 2021 | |
| Eusa Pharma (US) LLC | $44.62 | 2022 | |
| Merck Sharp & Dohme LLC | $34.02 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $33.91 | 2023-2024 | Onpattro |
| Horizon Therapeutics Plc | $32.43 | 2023 | Tepezza |
| Insmed, INC. | $27.95 | 2024 | Arikayce |
| Zealand Pharma US, INC. | $25.25 | 2022 | |
| Si-Bone, INC. | $24.15 | 2023 | |
| Azurity Pharmaceuticals, INC. | $24.00 | 2023 | Horizant |
| Smith+Nephew, INC. | $19.55 | 2024 | Renasys Go V2 Home |
| Esperion Therapeutics, INC. | $18.86 | 2022 | |
| Boston Scientific Corporation | $17.76 | 2021 | |
| Halozyme INC | $16.20 | 2023 | |
| Currax Pharmaceuticals LLC | $15.35 | 2022 | |
| Cequr Corporation | $15.32 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.